Details of the Drug-Related molecule(s) Interaction Atlas

L-733060 Drug Info

L-733060; L 733060; 148700-85-0; L-733,060 hydrochloride; L-733061; L 733061; L 733,061; L 733,060; L-733,061; CHEMBL27006; 3-((3,5-Bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine; L-733,060; (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine; Tocris-1145; AC1L31OI; Lopac0_000752; SCHEMBL1282817; CHEBI:92286; FCDRFVCGMLUYPG-ROUUACIJSA-N; ZINC3809445; BDBM50049468; AKOS030230939; CCG-204837; API0013970; NCGC00025030-02; NCGC00025030-01; KB-78050; l733060; LS-114326; BRD-K15791587-003-01-7

Cross-matching ID

PubChem CID

132846

ChEBI ID

CHEBI:92286

CAS Number

CAS 148700-85-0

TTD Drug ID

DMA1NJW

General Information of Drug (ID: DMA1NJW)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Substance-P receptor (TACR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[2]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[3]
Rolapitant	DM8XP26	Chemotherapy-induced nausea	MD90	Approved	[4]
Netupitant	DMEKAYI	Chemotherapy-induced nausea	MD90	Phase 3	[4]
Serlopitant	DM5VH6U	Prurigo nodularis	EC91.0	Phase 3	[5]
LY-686017	DM7WORZ	Atopic dermatitis	EA80	Phase 3	[6]
Elinzanetant	DMC6EFI	Hot flushes	GA30	Phase 3	[7]
CP-122721	DMSWLM5	Major depressive disorder	6A70.3	Phase 2	[8]
FR139317	DMEL5SV	Hypertension	BA00-BA04	Phase 2	[3]
VOFOPITANT HYDROCHLORIDE	DMQMYP5	Vomiting	MD90	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997).
2	Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
7	Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
8	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
9	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.